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Sleep that knits up the ravell’d sleave of care, 
The death of each day’s life, sore labour’s bath, 
Balm of hurt minds, great nature’s second course,  
Chief nourisher in life’s feast.  
 
William Shakespeare (Macbeth 2.2.48-51)  
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ABSTRACT 
 
Adenosine is an endogenous substance which, in addition to being a building block for high-
energy phosphates, has been associated with a multitude of both physiological and pathological 
processes including blood pressure, heart rate, pain and inflammation. In the central nervous 
system, adenosine is a recognized inhibitory neuromodulator, it is a neuroprotective agent  
against neuronal injury in threatening conditions like ischemia or epileptic seizures. In addition it 
is known to take part in the regulation of motor activity and sleep, among others. 
The sleep inducing effects of adenosine have been well documented, and it is known that this 
effect is at least partly mediated by adenosine A1 receptors. It is also known that during 
prolonged wakefulness adenosine accumulates specifically in the basal forebrain, a key area in 
the control of wakefulness and cortical activation. There is a transient increase in extracellular 
adenosine in the cortex, but no accumulation has been measured in any other area, including e.g. 
the thalamus and the dorsal raphe. As an inhibitory neuromodulator, adenosine inhibits the 
neuronal excitability in the basal forebrain, thereby decreasing cortical activity and increasing the 
propensity to sleep. 
This study was undertaken to clarify the mechanisms by which adenosine mediates its sleep 
inducing effects in the basal forebrain, and the possible mechanism(s) of adenosine accumulation 
at the cellular level in the rat. 
The mRNA expression and the receptor binding of the adenosine A1 and A2A receptors were 
measured after 3 and 6 hours of sleep deprivation and after 2 hours of recovery sleep. The A1 
mRNA was upregulated during sleep deprivation in the basal forebrain, while the receptor 
binding remained unchanged. In the olfactory tubercle, the A2A receptor mRNA expression was 
decreased, while the receptor binding showed a transient decrease to be lower after 3 but not after 
6 hours of deprivation. The adenosine A1 receptor-dependent G-protein activity, which directly 
measures the G-protein activity, was measured after 1, 2, 3 and 6 hours of deprivation, and after 2 
hours of recovery sleep. There was a transient increase of the G-protein activity in the cortex after 
2 and 3 hours of sleep deprivation, while the activity remained unaltered in the basal forebrain. 
On the basis of these data, it is concluded that accumulation of adenosine during prolonged 
wakefulness induces a fast transient response in the cortex, and a slow, longer lasting and 
possibly recovery sleep inducing response in the basal forebrain. 
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The activities of the main physiological regulators of extracellular adenosine concentrations, the 
enzymes adenosine kinase, ecto- and endo-5’-nucleotidase and the equilibrative nucleoside 
transporter ENT1, were measured after 3 and 6 hours of sleep deprivation and after 2 hours of 
recovery sleep. The enzyme activities were unaffected by sleep deprivation in both the cortex and 
the basal forebrain alike, while there was a decrease in the activity of the equilibrative nucleoside 
transporter ENT1 in the basal forebrain after 3 hours of sleep deprivation. It is concluded that the 
decrease of the ENT1 activity during prolonged wakefulness is at least one of the mechanisms 
causing the increase of extracellular adenosine concentrations during prolonged wakefulness. 
The distribution of both equilibrative nucleoside transporters, the ENT1 and the ENT2, in the 
central nervous system was assessed immunohistochemically by novel antibodies against the 
transporters, and their localization was demonstrated at the cellular level. Both transporters are 
expressed in practically all neurons, but the ENT1 is mostly associated with the cellular 
membrane and the ENT2 has a major intracellular localization. These data suggest that the ENT1 
is more directly connected to the transport of adenosine across the cell membrane, while the 
ENT2 has a more prominent role in the intracellular nucleoside transport in the rat central 
nervous system. 
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1. REVIEW OF THE LITERATURE 
 
1.1 Introduction 
 
Adenosine is the nucleoside base of adenosine triphosphate (ATP), which is the main high energy 
compound used in cellular metabolism. In addition to being a metabolic end product and a 
building block for high-energy phosphates, it is a modulator of several physiological and 
pathophysiological processes both in the body and in the central nervous system (CNS). It was 
already noted in 1929 that adenosine has profound effects on the mammalian heart (Drury & 
Szent-Gyorgyi 1929). In the 1970s the effects of adenosine and adenine nucleotides on cyclic 
adenosine monophosphate (cAMP) content on cortical slices were reported (Sattin & Rall 1970), 
followed by the confirmation of the existence of adenosine receptors (van Calker et al 1979). By 
1984 it was known that adenosine could affect at least vascular tone, hormone action, neural 
function, platelet aggregation and lymphocyte differentiation, and as by then substantial evidence 
had accumulated to show that  adenosine levels were at least partly regulated by metabolism of 
ATP and other nucleotides, Newby introduced the term “retaliatory metabolite” to express the 
idea that the cell could retaliate against an external stimulus which could cause excessive energy 
consumption with the metabolic end product itself (Newby 1984). In the CNS adenosine was by 
then known to inhibit synaptic activity and decrease neuronal excitability (Phillis et al 1979, 
Dunwiddie & Hoffer 1980, Phillis & Wu 1981) and to modulate cerebral blood flow (Berne et al 
1981). Since then adenosine has been acknowledged to take part in the regulation of sleep and 
arousal and to be a neuroprotective agent in situations like  ischemic or seizure-induced injury or 
trauma, which has led to intense research on its possible clinical use (Rudolphi et al 1992, 
Fredholm 1997, von Lubitz 1999, Dunwiddie & Masino 2001). 
 
1.2 Adenosine receptors 
 
Adenosine mediates its effects via specific receptors, namely  A1, A2A, A2B and A3 (Fredholm et 
al 2001). The first two adenosine receptors were cloned from a canine thyroid library (Libert et al 
1989) and they were later shown to be the A1 and A2A receptors (Maenhaut et al 1990, Libert et al 
1991). The A2B and A3 receptors have been cloned as well (Meyerhof et al 1991, Stehle et al 
1992). They are all seven transmembrane domain, G-protein coupled receptors (GPCRs) and 
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since the original findings they have been cloned from several species (Olah & Stiles 1995). The 
receptors differ in their affinity to adenosine, their distribution and function. The A1 and A2A are 
the high-affinity receptors, as they are activated already at nanomolar adenosine concentrations, 
while the A2B and A3 are activated only at micromolar concentrations (Fredholm et al 2000). 
Functionally the A1 and A3 are negatively coupled to adenylate cyclase by Gi/o and Gq/11 proteins 
and their activation leads to a decrease in the intracellular cAMP levels while the A2A and A2B are 
positively coupled to adenylate cyclase by Gs, Golf, Gq/11 and G15/16 and consequently their 
activation has an opposite effect on the cAMP levels (Fredholm et al 2000).  
The A1 receptor is  the most abundant and widely expressed of the adenosine receptors in the 
CNS, being most prominent in the hippocampus, cerebellum and cortex as shown by both mRNA 
expression studies and immunohistochemical staining (Reppert et al 1991, Rivkees et al 1995). 
Activation of the A1 receptors leads to inhibition of adenylate cyclase (van Calker et al 1978), 
stimulation of potassium conductance (Trussell & Jackson 1985), inhibition of Ca2+-conductance 
(Dolphin et al 1986) and activation of phospholipase C (Gerwins & Fredholm 1992). The net 
effect of A1 activation is a reduction in transmitter release pre-synaptically and post-synaptical 
hyperpolarization (Haas & Selbach 2000). 
The A2A receptor has a more localized expression in the CNS, being concentrated in the striatum, 
the nucleus accumbens, the olfactory tubercle and the lateral segment of globus pallidus (Jarvis & 
Williams 1989, Parkinson & Fredholm 1990) with a low expression throughout the rest of the 
CNS (Dixon et al 1996). The A2A receptor activates the adenylate cyclase pathway and seems to 
increase neurotransmission, but its role is not only stimulatory (Cunha 2001). The A2B and A3 
have a low expression in the CNS (Dixon et al 1996). They are activated only at pathological 
concentrations of adenosine and their physiological role is not clear (Haas & Selbach 2000). 
 
1.3 Regulation of extracellular adenosine levels 
 
1.3.1 General 
The extracellular levels of adenosine are in the nanomolar range under normal physiological 
conditions. Originally they were reported in the range of 30-50 nM using cerebral cortical cup 
technique (Phillis et al 1987). Later, the extracellular concentrations have been shown, using in 
vivo microdialysis, to be 120 nM in the cortex (Pazzagli et al 1994), 40-210 nM in the striatum 
(Ballarin et al 1991, Pazzagli et al 1993, Pazzagli et al 1995) and 180-270 nM in the basal 
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forebrain and the thalamus (Porkka-Heiskanen et al 2000). As the Km values of the A1 and the 
A2A receptors are in the nanomolar range (70 nM and 150 nM, respectively) (Dunwiddie & 
Masino 2001), it has been suggested that they are tonically active in physiological concentrations. 
This has been verified by recordings after antagonist infusions of both A1 and A2A receptors 
(Rainnie et al 1994, Svenningsson et al 1997). Thus a strict control of extracellular adenosine 
concentration is necessary to maintain the inhibitory tone at an appropriate level. 
As it is, the extracellular adenosine levels are regulated by extra- and intracellular metabolism 
and transport through the cell membrane (Fig. 1). There are two primary sources of extracellular 
adenosine. Firstly, it can be transported through the cell membrane according to the concentration 
gradient from the neighboring cells. This efflux of intracellular adenosine (which is often slightly 
misleadingly called release) occurs when energy expenditure exceeds energy production (i.e. 
more ATP is being degraded than produced), most prominently in situations like increased 
neuronal activity, seizures, ischemia or energy depletion (Lloyd et al 1993, Mitchell et al 1993, 
Brundege & Dunwiddie 1998). Secondly, adenosine can be produced extracellularly from 
adenosine nucleotides via the nucleotidase pathway (Zimmermann & Braun 1999). The primary 
source of adenosine for this pathway is ATP, which is known to be co-released with several 
neurotransmitters i.e. acetylcholine and noradrenaline (White 1977, Fredholm et al 1982, 
Poelchen et al 2001), and it has been shown that astrocytes can release adenosine nucleotides as 
well (Queiroz et al 1997).  
 
1.3.2 Extracellular production of adenosine 
Extracellularly, adenosine is formed by a chain of nucleotidases which degrade nucleotides into 
adenosine (Zimmermann & Braun 1999). ATP is hydrolyzed by ecto-ATPase and/or ecto-ATP 
diphosphorylase (Boeck et al 2002). Adenosine diphosphate (ADP) is dephosphorylated to 
adenosine monophosphate (AMP) by diphosphorylase as well. AMP is then dephosphorylated 
into adenosine by ecto-5’-nucleotidase (ecto-5’-NT, EC 3.1.3.5) (Zimmermann 1992). It is a 
membrane-bound ecto-enzyme with its active site in the extracellular space with a Km for AMP 
in the micromolar range, and it is competitively inhibited by ATP, ADP and ,-methylene 
adenosine diphosphate (AOPCP) (Zimmermann 1996). In the rat CNS it has been shown to be 
localized on glial cells with the exception of the mossy fiber terminals in the CA3 region of the 
hippocampus (Schoen et al 1987, Zimmermann et al 1993, Schoen et al 1999). Yet ecto-5’-NT 
activity has been noted on neural and glial cells using both biochemical and 
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immunohistochemical methods (Franco et al 1986, Cunha et al 1992, James & Richardson 1993). 
This discrepancy has been attributed to possible immunologically distinct isoforms of the enzyme 
in the CNS (Zimmermann et al 1993, Cunha et al 2000). The degradation of nucleotides into 
adenosine is fast, extracellular ATP is abolished and metabolized into adenosine in less than 1 
second, the dephosprohylation of AMP into adenosine being the rate-limiting step  (Dunwiddie et 
al 1997).  
 
 
 
 
SAHH 
 
AMP 
 
ADP 
 
ATP 
AK 
Inosine 

SAH 
ADA 
ecto-5’-NT 
ENT1 and ENT2 
ATP 
 
ADP 
 
AMP 

endo-5’-NT 
CNTs 
Figure 1. A simplified schema of the main intra- and extracellular pathways of adenosine 
metabolism and transport. Extracellularly adenosine is formed by a chain of 
ectonucleotidases, of which the ecto-5’-nucleotidase (ecto-5’-NT) is the rate limiting 
enzyme. Intracellular formation of adenosine is due to a similar chain of nucleotidases 
with the endo-5’-nucleotidase (endo-5’-NT) being the rate limiting enzyme. Adenosine is 
degraded either into adenosine monophosphate (AMP) by adenosine kinase (AK) or into 
inosine by adenosine deaminase (ADA). A third adenosine metabolizing enzyme is S-
adenosylhomocysteine (SAH)-hydrolase (SAHH) which converts SAH into adenosine, or 
vice versa, but it is thought to have a lesser role. Adenosine in transported through the cell 
membrane either by the sodium-driven concentrative nucleoside transporters (CNTs) or 
according to the concentration gradient by equilibrative nucleoside transporters 1 and 2 
(ENT1 and ENT2, respectively). ATP= adenosine triphosphate, ADP= adenosine 
diphosphate. 
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An alternate source for extracellular adenosine formation is cAMP, as it has been shown that 
norepinephrine and vasoactive intestinal peptide induce extracellular accumulation of cAMP and 
adenosine in cortical cultures (Rosenberg & Dichter 1989, Rosenberg & Li 1995a, Rosenberg & 
Li 1995b). In support of these findings, it has been shown that prolonged superfusion of 
hippocampal slices with cAMP increases extracellular adenosine formation, but as short periods 
of increased cAMP levels do not affect adenosine formation, it has been speculated that cAMP 
would cause only slow responses in extracellular adenosine concentrations (Brundege et al 1997). 
 
1.3.3 Intracellular production of adenosine 
Intracellularly, adenosine is formed by at least three different endo-5’-nucleotidases. Two of 
them have high Km values, one of which prefers AMP (Km for AMP 1-14 mM) and the other 
inosine monophosphate (IMP) as substrate (Zimmermann 1992). The third endo-5’-nucleotidase 
resembles the ecto-enzyme, it has a low Km of 14 µM for adenosine and it is likely to have a 
major role in adenosine production under physiological concentrations (Orford & Saggerson 
1996). 
Another possible source of intracellular adenosine could the hydrolysis of S-adenosyl 
homocysteine (SAH) by the SAH-hydrolase (SAHH, EC 3.3.11). In the rat brain there is 
evidence showing it to be mainly nuclear and present in several brain regions (Patel & Tudball 
1986). Furthermore, it has been shown in chick embryos that SAHH has higher activity in the 
neurons than glia (Ceballos et al 1994). The hydrolysis reaction catalyzed by the SAHH is fully 
reversible, but as the L-homocysteine levels are very low in the brain, it is thought that the main 
direction is the hydrolysis of SAH into adenosine and L-homocysteine and not vice versa 
(Reddington & Pusch 1983). 
The SAHH is responsible for approximately one third of the adenosine production in the guinea 
pig heart, but it is not closely linked to the energy state of the cells (Lloyd et al 1988, Deussen et 
al 1989). In the rat hippocampal slices, it has been shown that the inhibition of the SAHH does 
not affect the extracellular adenosine levels under basal conditions (Pak et al 1994), under 
ischemia-like conditions or during electrical stimulation (Lloyd et al 1993, Latini et al 1995). 
Thus the SAHH is thought to have a minor role, if any, in the metabolism of adenosine in the rat 
brain (Brundege & Dunwiddie 1997). 
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1.3.4 Intracellular metabolism of adenosine 
There are two intracellular metabolic pathways which lead to a decrease in adenosine levels: 
phosphorylation of adenosine into AMP by adenosine kinase (AK, EC 2.7.1.20) or deamination 
of adenosine into inosine by adenosine deaminase (ADA, EC 3.5.4.4). 
AK is a soluble enzyme located in the soma of the cells. It is a low Km enzyme (2µM) located 
quite evenly in the rat CNS, whose activity is inhibited with concentrations higher than 0.5 µM 
(Phillips & Newsholme 1979, Yamada et al 1980). Inhibition of AK has been shown to increase 
adenosine levels under basal and stimulated conditions (Pak et al 1994, Lloyd & Fredholm 1995, 
White 1996) and quite recently it was noted that there is an increase in AK expression and a 
decrease in adenosine concentrations after a kainate induced lesion in the mouse hippocampus 
(Gouder et al 2004). 
ADA, unlike AK, shows a more selective distribution in the rat CNS, being most prominent in 
the basal hypothalamus as has been shown by both immunoreactivity and enzyme activity 
measurements (Phillips & Newsholme 1979, Nagy et al 1984). In addition high enzyme activity 
has been noted in the tuberomamillary nucleus (Mackiewicz et al 2000) and a high mRNA 
expression in the leptomeninges (Okada et al 2003). The Km for ADA is approximately 17-45 
µM in the rat brain (Phillips & Newsholme 1979), and although it is considered to be an 
intracellular enzyme, there is evidence of extracellular ADA as well (Franco et al 1986). 
Selective ADA inhibitors, deoxyformycin and erythro-9-(2-hydroxy-3-nonyl)adenosine (EHNA), 
have been shown to increase extracellular adenosine levels both under basal conditions and under 
hypoxia and ischemia in vivo (Phillis & O'Regan 1989, Ballarin et al 1991, Phillis et al 1991, 
Pazzagli et al 1993, Sciotti & Van Wylen 1993, Pazzagli et al 1995). In in vitro studies EHNA 
has been shown to have no effect under basal conditions or after electrical field stimulation 
(Lloyd & Fredholm 1995, White 1996), but in the same study EHNA did increase adenosine 
levels after energy depletion (Lloyd & Fredholm 1995). In hippocampal slices the endogenous 
ADA did not affect extracellular adenosine levels under basal or hypoxic conditions (Pak et al 
1994, Zhu & Krnjevic 1994). 
As the physiological adenosine concentrations are in the nanomolar range, it is likely that 
phosphorylation of adenosine by AK is the prominent pathway for metabolizing adenosine under 
normal physiological conditions and that the deamination by ADA becomes more prominent as 
the adenosine concentrations increase into the micromolar range, like during seizures and 
ischemia. 
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1.3.5 Adenosine transport 
In addition to adenosine production and degradation, the extracellular adenosine levels are 
regulated by adenosine transport through the cell membrane. There are two families of 
transporters: the concentrative nucleoside transporters (CNT) and the equilibrative nucleoside 
transporters (ENT) (Thorn & Jarvis 1996). The CNT-type transporters are high-affinity 
transporters and are, as their name indicates, concentrative, and thus facilitate the influx of 
adenosine and other nucleosides, driven by the transmembrane sodium gradient. Five different 
CNTs have been described in man (Cabrita et al 2002), of which CNT1, CNT2 and CNT3 belong 
to the SLC28 gene family (Gray et al 2004). Two of them, CNT1 and CNT2, have been shown to 
be expressed in the rat brain (Anderson et al 1996). The role of CNTs in the regulation of the 
extracellular adenosine concentrations is not known; while it is thought to be less important than 
that of ENTs, it should be noted that the lack of specific pharmacological tools has hindered 
research on them (Cabrita et al 2002).  
The ENT-type transporters carry nucleosides across the cell membrane in either direction 
according to the concentration gradient (Thorn & Jarvis 1996). The localization of transporter 
sites in the rat brain was originally reported using [3H]NBMPR-binding studies (Geiger & Nagy 
1984, Bisserbe et al 1985). Shortly thereafter functional studies indicated the presence of two 
different transporters (Lee & Jarvis 1988), which was later confirmed with in situ -hybridization 
studies (Anderson et al 1999a, Anderson et al 1999b).  
The ENTs were originally divided on the basis of their sensitivity to the inhibitor 
nitrobenzylthioinosine (NBMPR). The equilibrative NBMPR-sensitive (es) transporters are 
inhibited by nanomolar concentrations and the equilibrative NBMPR-insensitive (ei) transporters 
are inhibited only by micromolar concentrations of NBMPR. Later, when the transporters were 
cloned in rat (Yao et al 1997) and humans (Griffiths et al 1997), they were renamed ENT1 and 
ENT2 (es and ei, respectively). While the ENT2 transporter lacks a specific inhibitor,  NBMPR  
can be used as a relatively specific inhibitor for the ENT1 transporter. NBMPR binds dose-
dependently to the ENT1 transporter with high affinity, blocking the adenosine transport. This 
binding is inhibited by other adenosine transporter inhibitors in a saturable manner, e.g. 
dipyridamole (Jarvis & Young 1980, Thorn & Jarvis 1996). Due to these properties, the tritium-
labelled NBMPR has been used to measure the ENT1 activity since the early studies on 
nucleoside transporters (Thorn & Jarvis 1996). 
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Of the two transporters the ENT1 has been thought to be the more important due to its greater 
activity (Cabrita et al 2002), but it has been suggested that the ENT2 would be the more 
important transporter in the rat brain due to a higher mRNA expression (Anderson et al 1999a). 
 
1.4 Adenosine and sleep 
 
1.4.1. General 
The first report on the hypnogenic properties of adenosine goes back to the middle of the last 
century, when it was shown that injections of adenosine into the lateral ventricle induced sleep-
like behaviour in the cat (Feldberg & Sherwood 1954) and two decades later the same 
phenomenon was noted in dogs (Haulica et al 1973). Since then adenosine has been in the focus 
of sleep research and its hypnotic properties have been noted repeatedly as both adenosine and its 
agonist induce sleep in rats (Dunwiddie & Worth 1982, Virus et al 1983, Radulovacki et al 1984, 
Radulovacki 1985, Ticho & Radulovacki 1991). Restoration of energy has been suggested to be 
one function of sleep (Chagoya de Sanchez et al 1993, Benington & Heller 1995), and adenosine 
has fit well into the theory as it is a metabolic end product; the more energy spent, the more sleep 
is needed to restore the energy stores. Furthermore, the most widely used pscyhoactive stimulant 
in the world, caffeine, is an adenosine receptor antagonist (Fredholm et al 1999). 
 
1.4.2 Extracellular adenosine levels during the sleep-wake cycle 
Extracellular adenosine concentrations are known to increase during both increased neuronal 
activity and increased metabolism (Pull & McIlwain 1972, Van Wylen et al 1986, Mitchell et al 
1993). On the other hand, wakefulness is known to have greater metabolic activity which has 
been shown by measuring glucose utilization, cerebral blood flow and oxygen consumption in 
humans (Madsen et al 1991, Maquet et al 1992, Madsen 1993, Maquet et al 1997) and 
extracellular glucose and lactate concentrations in rats (Netchiporouk et al 2001, Shram et al 
2002). 
Thus it could be expected that adenosine concentrations vary during the sleep-wake cycle. It was 
first shown that the extracellular adenosine levels were lower during the rest phase and higher 
during the active phase in the hippocampus and neostriatum of rats (Huston et al 1996). The first 
direct evidence for state-dependency was published in 1997 when it was shown using in-vivo 
microdialysis that the extracellular adenosine levels were higher during slow-wave sleep than 
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during waking in the cholinergic magnocellular basal forebrain (BF) and the thalamus of cats 
(Porkka-Heiskanen et al 1997). Later this phenomenon was shown to be present also in the 
cortex, the dorsal raphe nucleus, the pedunculopontine tegmental area (PPT) and the preoptic 
hypothalamic area (Porkka-Heiskanen et al 2000). Recently the state-dependency and the 
circadian variation have been further confirmed in the BF of both young and old rats (Murillo-
Rodriguez et al 2004). 
 
1.4.3 The cholinergic basal forebrain and local accumulation of adenosine during prolonged 
wakefulness 
The BF is part of the extrathalamic ventral pathway from the brainstem reticular activating 
system to the cerebral cortex (Steriade 1996, Jones 2004). It is a heterogenous region in the 
ventral region of forebrain adjacent to preoptic, supraoptic and rostral infundibular levels of the 
hypothalamus. During the last decades the BF has been connected with several behavioural 
functions like attention (Muir et al 1994), cortical arousal (Buzsaki & Gage 1989, Berntson et al 
2002),  control of sensory processing (Metherate & Ashe 1993, Sarter & Bruno 1997),  learning 
and memory (Bartus et al 1982, Fibiger 1991, McLin, III et al 2002), plasticity (Kilgard & 
Merzenich 1998) and sleep (Szymusiak 1995).  
The BF contains magnocellular cholinergic neurons which innervate widely the limbic system 
and the cortex providing most of the cholinergic cortical innervation (Jones 2004). The 
cholinergic cells are located interdispersed in several nuclei, from rostral to caudal: the medial 
septum, the vertical and horizontal diagonal bands of Broca, the magnocellular preoptic are, the 
substantia innominata and the nucleus basalis of Meynert (Cullinan & Zaborszky 1991). Even 
though the BF was originally named according to the cortically projecting magnocellular 
cholinergic neurons, these cholinergic neurons are a minority and actually outnumbered by 2:1 
the rat BF by GABAergic neurons, which have cortical projections as well. In addition, there is a 
substantial proportion of unidentified cortically projecting neurons (Rye et al 1984, Gritti et al 
1993, Gritti et al 1997). 
The cholinergic cortically projecting neurons of the BF release acetylcholine (ACh) which 
excites the cortical neurons and thus stimulates cortical activation (Krnjevic 1967, McCormick & 
Prince 1986, McCormick 1992). This ACh release has been shown to be highest during waking 
and REM sleep (Celesia & Jasper 1966, Jasper & Tessier 1971, Marrosu et al 1995). 
Furthermore, lesions of the BF have been shown to disrupt sleep patterns of of both cats and rats 
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(Stewart et al 1984)(Szymusiak & McGinty 1986b, Buzsaki et al 1988), and the discharge rates 
of the supposedly cholinergic neurons have been shown to be highest during waking and REM 
sleep while being lowest during slow-wave sleep (SWS) in both cats and rats (Detari et al 1984, 
Szymusiak & McGinty 1986a, Szymusiak & McGinty 1989, Alam et al 1999). 
The idea for the connection between adenosine and the cholinergic systems rose when it was 
shown in vitro that A1 agonists decreased and antagonist increased the neuronal discharge rate in 
the cholinergic mesopontine laterodorsal and peduculopontine tegmental nuclei (LDT/PPT) by 
causing hyperpolarization of identified cholinergic cells (Rainnie et al 1994). Later it was shown 
in vivo that infusion of adenosine via microdialysis cannula into the BF and the LDT/PPT of cats 
(Portas et al 1997) and the BF of rats (Basheer et al 1999) induces sleep. 
In addition to being a sleep inducing agent, adenosine was noted to accumulate in the BF of cats 
and rats during prolonged wakefulness (Porkka-Heiskanen et al 1997, Basheer et al 1999) This 
effect is site specific as it is present only in the BF and transiently in the cortex (Porkka-
Heiskanen et al 2000). Furthermore, it has been shown with combined in vivo microdialysis and 
unit recording that infusion of adenosine into the BF of rats  and cats  decreases the unit activity 
of the cortically projecting wake-related neurons (Alam et al 1999, Thakkar et al 2003a). 
 
1.4.4 The roles of the A1 and A2A receptors during prolonged wakefulness 
The A1 receptors have been associated with the regulation of the sleep-wake cycle since it was 
noted that A1 agonist N6-cyclopentyladenosine (CPA) induced sleep when given i.p. or i.c.v. 
(Benington et al 1995, Schwierin et al 1996). Later it has been shown that unilateral infusion of 
A1 receptor antagonist cyclopentyl-1,3-dimethylxanthine (CPT) into the BF of cats and rats 
increases waking and decreases sleep (Strecker et al 2000). Combined microdialysis and unit 
recording studies have shown that infusion of A1 agonist into the BF decrease, and infusion of A1 
antagonist increase single unit activity of wake-active neurons in both cats and rats (Alam et al 
1999, Thakkar et al 2003a). Recently it has been shown that bilateral infusion of antisense to the 
A1 receptor mRNA decreases non-REM sleep and induces wakefulness (Thakkar et al 2003b). In 
this method, the antisense binds to the A1 receptor mRNA preventing the translation of mRNA 
which is thought to lead to a decreased amount of receptor protein. In addition to decreasing sleep 
and inducing wakefulness the rats had less non-REM sleep after 6 hours of sleep deprivation 
(SD) when compared to untreated controls. When considering the evidence presented above, the 
A1 receptors have an important role in the homeostatic regulation of sleep in the BF. 
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There is another line of evidence promoting the importance of A1 receptors. It has been shown 
that the activation of the A1 receptors in the BF mobilizes intracellular calcium in vitro mainly in 
the cholinergic cells (Basheer et al 2002) and that a SD induced increase in extracellular 
adenosine levels increases c-FOS protein levels and  NF-B binding, both known transcription 
factors, in the BF (Basheer et al 1999). This suggests that adenosine (and SD) has longer lasting, 
possibly gene transcription affecting and recovery sleep inducing effects in addition to the 
immediate hyperpolarizing inhibitory effects in the BF (Basheer et al 2001). 
The A2A receptors are involved in the regulation of sleep, as it has been shown that infusion of 
A2A agonists into the subarachnoid space under the rostral basal forebrain induces sleep (Satoh et 
al 1996, Satoh et al 1998, Satoh et al 1999).  Furthermore, it has been shown that activation of 
prostaglandin D2 receptors in the rostal basal forebrain leads to release of adenosine, the 
activation of adenosine A2A receptors and an increase in non-REM sleep (Matsumura et al 1994, 
Urade & Hayaishi 1999, Mizoguchi et al 2001, Hayaishi 2002). The sleep inducing effects of the 
prostaglandin D2 and A2A agonist have been localized in the ventrolateral preoptic area (VLPO) 
(Scammell et al 1998, Scammell et al 2001), an area which is known to contain GABAergic, 
sleep-active cells projecting into wake-promoting regions such as the tuberomamillary nucleus 
(Sherin et al 1996, Sherin et al 1998, Szymusiak et al 1998, Gallopin et al 2000). Quite recently it 
has been shown that the sleep-active neurons in VLPO are disinhibited by adenosine (Morairty et 
al 2004). Most of the studies concerning the sleep inducing effects of A2A in the VLPO have been 
conducted using pharmacological approaches or micromolar adenosine concentrations. Therefore 
future research is needed to clarify the role of adenosine in controlling the activity of VLPO 
under normal sleep-wake cycle and prolonged wakefulness. 
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2. AIMS OF THE STUDY 
 
General aims of the study: 
When starting this study, it was well documented that adenosine accumulates during prolonged 
wakefulness especially in the BF and that it has sleep inducing properties which are at least 
partially mediated by the A1 receptors.  
The following main questions were set: 
 
1. By which mechanism(s) does the adenosine accumulate in the BF and the cortex during 
prolonged wakefulness?  
2. What is the mechanism(s) by which the recovery sleep inducing effects are mediated in 
the BF? 
 
 
Specific aims of the study: 
 
I. To find out whether the prolonged stimulation due to the accumulation of adenosine 
during SD has effects in the affinity or transcription of the A1 and the A2A receptors. 
II. To clarify the possible changes in the A1 receptor mediated G-protein activation during 
prolonged wakefulness. 
III. To find out whether the activities of the key adenosine metabolizing enzymes are affected 
during prolonged wakefulness. 
IV. To study possible changes in the activity of the equilibrative nucleoside transporter ENT1, 
the other possible mechanism affecting the extracellular levels of adenosine. 
V. To show the localization of the equilibrative nucleoside transporters ENT1 and ENT2 at 
the cellular level as differences in the localization can have significance in the regulation 
of extracellular adenosine concentrations. 
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3. MATERIALS AND METHODS 
 
As the experimental procedures are described in detail in the original publications included in this 
thesis, only general information on the experimental techniques is reported here. Unless 
otherwise stated, the experiments were performed at the Institute of Biomedicine, University of 
Helsinki. 
 
Experimental animals (I-V) 
Adult male Hannover Wistar rats (weight 260-390g), were used in the experiments. In addition, 
male Long Evans rats (weight 350-450g) were used in RT-PCR experiments which were 
conducted at Harvard University (I). The Wistar rats were purchased from the Experimental 
Animal Center of the University of Helsinki and kept in 12/12h light/dark rhythm with free 
access to standard rat chow and water. All experimental protocols were approved by the 
respective ethical committees and were in accordance with the laws of Finland and the European 
Convention. 
 
Sleep deprivation (I-IV) 
Rats were sleep-deprived (SD) for 1 to 6 hours by the previously described gentle handling 
method (Franken et al 1993) starting at lights on (n=6 in all groups) as follows: in all studies 
involving SD (I-IV) rats were deprived for at least for 3 and 6 hours. In addition, in the studies 
assessing the adenosine A1 receptor mediated G-protein activity (II), the activities of the 
adenosine metabolizing enzymes (III) and the ENT1 transporter activity (IV), an additional group 
was allowed to sleep for 2 hours after 6 hours of SD. Finally, in the G-protein activity study (II), 
additional 1 and 2 hour deprivations were carried out. 
A time matched control group, which was kept undisturbed in their home cages, was used for 
each experimental group. At the end of the SD, the rats were decapitated at the same time with 
their corresponding controls and the brains were rapidly removed. The use of time-matched 
controls makes it possible to dissociate the circadian and homeostatic components (thus making it 
possible to assess the effects of sleep deprivation per se). The 1 hour SD group was the only 
exception, and the values obtained from this group were compared to the 2 hour SD controls, as a 
time difference of 1 hour is unlikely to cause major differences in G-protein activity under 
normal resting conditions. 
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In situ hybridization (I,IV) 
The mRNA expression of the rat ENT1 (IV) and of the A1 and the A2A receptors (I) was assessed 
as previously described (Johansson et al 1993, Toppila et al 1996). 
 The brain was cut into 20 µm coronal cryosections. Sections were post fixed in 
paraformaldehyde and incubated with a 35S labeled oligonucleotide probe. The different probes 
were complementary to mRNA sequences of the desired proteins; the rat ENT1 probe was 
complementary to nucleotides 763-810 of the rat ENT1 (Yao et al 1997), the A1 probe to 
nucleotides 985-1032 of the rat A1 receptor (Mahan et al 1991) and the A2A probe to nucleotides 
916-959 of the dog A2A receptor (Schiffmann et al 1990). The labeled mRNA was then visualized 
with emulsion autoradiography and the rat ENT1 mRNA expression was measured by computer 
densitometry as previously described (Toppila et al 1997). The A1 and the A2A receptor mRNA 
expression was assessed in Karolinska Institutet, Stockholm. 
 
RT-PCR (I) 
The cDNA was created from extracted total RNA by using reverse transcriptase and specific 
primers for A1 receptors and cyclophylin. The cDNAs were then amplified by polymerase chain 
reaction. The amplified sequences were separated by electrophoresis on polyacrylamide gel and 
visualized with phosphoimager, and the A1/cyclophylin ratio was calculated. These experiments 
were performed at the Department of Psychiatry, Harvard Medical School. 
 
A1 and A2A receptor  autoradiography (I) 
Receptor autoradiography was assessed as previously described (Parkinson & Fredholm 1992, 
Johansson et al 1993). Coronal sections were cut and incubated in the presence of 0.25-10 nM 
tritium labeled 1,3-dipropyl-8-cyclopentylxanthine (DPCPX) or 0.2-10 nM tritium labeled 5-
amino-phenylethylfurylpyrazolo-1,2,4-triazolo-pyrimidine (SCH 58261) for detection of A1 and 
A2A receptors, respectively. The receptors were visualized autoradiographically. The experiments 
were performed in Karolinska Institutet. 
 
[35S]Guanosine 5’-(-thio)triphosphate autoradiography (II) 
The binding assay was performed  as previously described (Laitinen 1999).  Coronal sections were 
incubated in the presence of [35S]GTPS, excess GDP, ADA to abolish the endogenous adenosine 
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and A1 receptor agonist 2-chloroadenosine at two concentrations producing near maximal and 
maximal responses (10-5 and 10-4 M, respectively). The bound [35S]GTPS was visualized 
autoradiographically. The autoradiography assay was done at the Department of Physiology, 
University of Kuopio. 
 
Measurement of adenosine kinase activity (EC. 2.7.1.20) (III) 
The AK activity was analysed radiochemically by monitoring the conversion of [2-3H]-adenosine 
into [3H]-AMP as previously described (Ward et al 1998). The membranous and soluble fractions 
were separated by centrifugation and the supernatant was incubated in the presence of EHNA, 
excess ATP and [3H]-adenosine. The reaction product, [3H]-AMP, was bound to ammonium 
formate equilibrated DEAE-Sephadex and then eluted with formate buffer. The eluate was taken 
for scintillation counting. 
 
Measurement of the 5’-nucleotidase activities (EC 3.1.3.5) (III) 
Both endo- and ecto-5’-nucleotidases were assayed by monitoring the conversion of [2-3H]-AMP 
into [3H]-adenosine with a previously described method  (Orford et al 1991). The membranous 
and soluble fractions were separated by centrifugation and the membrane fraction was used for 
the ecto-5’-NT activity measurements while the endo-5’-nucleotidase activity was measured from 
the soluble fraction.  The samples were incubated in the presence of [2-3H]-AMP and an excess 
of AMP. The reaction was stopped by desiccation and the activity was measured from the 
remaining supernatant using scintillation counting. 
 
NBMPR binding (IV) 
The NBMPR binding was determined as previously described (Williams et al. 1984) with 
slight modifications. The membrane fraction was separated from the tissue samples and the 
NBMPR binding was measured by incubating the membranes in the presence of tritium 
labeled NBMPR. Radioactivity was measured from the filters using scintillation counting. 
 
Raising the antiserum for rat ENT1 and ENT2 (V) 
A 13- and 14-amino acid sequences were synthesized based on published sequences of the rat 
ENT1 and the rat ENT2, respectively (Yao et al 1997). The synthesized peptides contain 
amino acid residues 59-77 for the rat ENT1 and 50-63 for the rat ENT2. An additional cystein 
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residue was attached to the N-terminus and the peptide was coupled to a carrier molecule, 
either limpet keyhole haemocyanin or thyroglobulin. New Zealand rabbits were immunized 
with the rat ENT1- or the rat ENT2-haemocyanin conjugate emulsified with Freund´s 
complete adjuvant. Pre-immune serum samples from all the rabbits were collected before the 
immunization to be used as control sera. The animals were test bleeded to verify immunization 
by dot blotting. 10 days after a further booster, the animals were sacrificed and their blood was 
collected, serum separated and stored at -80 ºC.     
 
Dot-blotting (V) 
A dilution series of the ENT1 and the ENT2 -thyroglobulin conjugates (100 µg/ml - 10 ng/ml) 
were pipetted onto nitrocellulose slips. The slips were incubated with the rat ENT1 or rat 
ENT2 antisera. The immunocomplexes were visualized with horse radish peroxidase-
conjugated secondary antibody and diaminobenzidine (DAB) as a chromogen. 
 
Western blotting (V) 
Aliquots of homogenized rat tissue samples containing cortex, hippocampus, hypothalamus, 
brain stem or cerebellum were weight fractioned on polyacrylamide gel. The separated 
proteins were transferred onto nitrocellulose filters, which were incubated with the ENT1 or 
the ENT2 antibody and horse radish peroxidase-conjugated secondary antibody. DAB was 
used as a chromogen. 
 
Immunohistochemistry (V) 
Male Wistar rats were perfused transcardially with 4 % paraformaldehyde under sodium 
pentobarbital anaesthesia. Sections were incubated with the primary antibody at 4ºC overnight 
in a humidity chamber. The ENT1 and the ENT2 antisera and the corresponding pre-immune 
serum were used in dilutions 1:500-1:1 000. After incubation with the primary antibody, the 
sections were incubated with horse radish peroxidase-conjugated secondary antibody, and 
DAB was used as a chromogen. 
 
Double staining studies (V) 
Sections were equal to the ones used for single antibody stainings. The sections were 
incubated with the rabbit-raised ENT1 or ENT2 antiserum (1:500), and one of the following 
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monoclonal antibodies; antibody against neuron-specific antigen NeuN (1:1000), antibody 
against astrocyte-specific antigen S-100 (1:2000), antibody against oligodendrocyte-specific 
antigen (1:10000) or antibody against oligodendrocyte-specific antigen OX-42 (1:100). 
Fluorescein- and rhodamine-conjugated secondary antibodies were incubated consecutively, 
for 1 h each. The stainings were visualized with fluorescence-microscopy. 
 
Specificity of  antibodies (V) 
Based on genome bank search, the amino acid sequences used for immunization for ENT1 and 
ENT2 are not present in any other known peptide. Omitting the primary (ENT1 or ENT2) 
antiserum removed all staining. In immunofluorescence specimens a faint background 
autofluorescence was seen. Staining with the pre-immune sera obtained from the same rabbit in 
which the respective ENT antibody was raised resulted in no staining above the background 
level. Specificity of the other antibodies used in the study has been described before (for anti-
NeuN (Wolf et al 1996); for anti-S-100 (Boyes et al 1986); for anti-oligodendrocyte (Friedman 
et al 1989); for anti-OX-42 (Ford et al 1995) ). 
 
Statistics (I-IV) 
The effect of SD on the adenosine A1 and A2A receptor ligand binding and mRNA expression (I) 
was evaluated using Student’s t-test for the RT-PCR experiments, unpaired t-test for the in situ 
hybridization experiments and one-way analysis of variance (ANOVA) for the ligand binding 
experiments. 
The effect of  SD on adenosine A1 receptor dependent G-protein activation (II), enzyme activities 
(III) and ENT1 transporter activity (IV) was evaluated using Student’s t-test by comparing the 
values from the sleep deprived animals to the values from the undisturbed control animals 
decapitated at the same circadian time. The effect of diurnal variation was evaluated from the 
undisturbed control animals using one-way ANOVA with Student-Newman-Keuls as post hoc 
test (II-IV). The difference between the groups was regarded as significant at p<0.05. 
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4. RESULTS AND DISCUSSION 
 
4.1 The effects of sleep deprivation on adenosine A1 and A2A receptors 
 
4.1.1 Ligand binding and mRNA expression of the A1 and the A2A receptors during prolonged 
wakefulness (I) 
At the time this study was undertaken, it was known that adenosine accumulates in the BF of 
both rats and cats during prolonged wakefulness and that infusions of adenosine and adenosine 
A1 receptor agonists into the BF induce sleep (Porkka-Heiskanen et al 1997, Portas et al 1997, 
Basheer et al 1999, Porkka-Heiskanen et al 2000). On the other hand, there was evidence 
showing that the A2A receptors are involved in the regulation of sleep, as A2A agonists induce 
sleep in the rostral forebrain (Satoh et al 1996). The possible mechanisms mediating the sleep 
inducing effects of adenosine in the BF were unknown, as were the possible effects of the 
sustained agonist stimulation present during prolonged wakefulness. As a first step to study the 
effects of adenosine on its receptors during prolonged wakefulness, the ligand binding and 
mRNA expression of the A1 and A2A receptors were measured after 3 and 6 hours of SD. 
The ligand binding of the A1 receptors was measured from both the BF and the cortex and it 
remained unaltered in both areas during the SD. In the cortex, the A1 mRNA was not affected, 
while in the BF the A1 mRNA expression was increased. This increase suggests a positive 
feedback mechanism of A1 receptors during prolonged wakefulness. The most common response 
of the GPCRs to prolonged agonist exposure is receptor downregulation (Grady et al 1997) which 
has been noted in A1 receptors before (Fredholm et al 2001). On the other hand, there is evidence 
showing that A1 receptors are being upregulated during threatening conditions like ischemia in 
smooth muscle cells (Hammond et al 2004) and hypoglychemia has been shown to induce A1 
receptor activation and to participate in hypoglychemia induced neuronal death in cortical 
neurons (Turner et al 2004). As energy depletion mimicks the effects of sleep deprivation 
(Kalinchuk et al 2003), it would be tempting to hypothesize that during prolonged wakefulness 
adenosine induces in the BF changes similar to those induced by hypoglychemia in the cortex. 
There seems to an upregulation of A1 receptors, i.e. positive feedback, in situations where the 
reduction of signalling could be potentially harmful. In such situations, the receptor expression 
must be upregulated to maintain, and possibly increase, the inhibitory tone until the potentially 
harmful situation is avoided, in the case of prolonged wakefulness, until sleep is initiated. 
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The importance of the A1 receptors was confirmed in our studies in an undirect manner, as the 
A2A receptor mRNA was not expressed in the BF with either in situ hybridization or RT-PCR 
suggesting the lack of A2A receptors in this region. 
The ligand binding and the mRNA expression of the A2A receptors were measured from the 
striatum, the nucleus accumbens and the olfactory tubercle. It was found that both the ligand 
binding and the mRNA expression were decreased during sleep deprivation in the olfactory 
tubercle, but not in the nucleus accumbens or the striatum. The ligand binding was decreased 
only after 3 but not after 6 hours of SD, while the mRNA expression was significantly decreased 
after both 3 and 6 hours of SD. The extracellular concentrations of adenosine have not been 
measured from the olfactory tubercle during normal sleep-wake cycle or prolonged wakefulness. 
If there is an increase in the extracellular adenosine concentrations, the decreases in ligand 
binding and mRNA expression are not suprising, as the A2A receptors are known to be rapidly 
desensitized and downregulated after prolonged exposure to stimuli (Moreau & Huber 1999). 
 
4.1.2. The A1 receptor mediated signaling is transiently increased in the cortex (II) 
It was shown in the previous experiments (I) that the adenosine A1 receptor mRNA expression 
increased in the basal forebrain and remained unaltered in the cortex, while the ligand binding 
remained unaffected. In order to further clarify the activation of the A1 receptors, it was decided 
to measure the A1 receptor dependent G-protein activity, i.e. the A1 receptor mediated signalling 
using  the [35S]GTPS autoradiography, a method developed by our collaborator Jarmo Laitinen 
(Laitinen 1999). With this method, it is possible to assess the G-protein activity directly and in 
situ, which omits the possible pitfalls of ligand binding and mRNA expression assays. 
The rats were sleep deprived for 1, 2, 3 or 6 hours and one group was allowed to sleep 2 hours of 
recovery sleep after 6 hours of SD. The A1 receptor-stimulated [35S]GTPS binding was 
transiently increased in both the frontal and the cingulate cortex after 2 and 3 hours of  SD, while 
a smaller increase was noted in the medial preoptic area (MPA) after 3 hours of SD. In the BF, 
the [35S]GTPS binding remained unaltered throughout the deprivation and recovery sleep. The 
increase in the G-protein activity in both cortical areas was most prominent after 2 hour SD and 
started to diminish already after the third hour of SD.  
The major finding was the rapid and transient increase in A1 receptor-dependent G protein 
activity during prolonged wakefulness in the cortex, while A1 receptor signalling remained 
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unaltered in the BF. To our best knowledge, this was the first study to assess adenosine A1 
receptor-mediated signalling directly and in situ during prolonged wakefulness.  
A major feature and advantage of the GPCRs is signal amplification which takes place in several 
stages; firstly, the activation of one receptor can activate several G-proteins which leads to the 
dissociation of the - and -subunits, secondly, both activated subunits affect multiple different 
effectors, i.e. adenylyl cyclase, protein kinase C etc. and thirdly, the activated effectors have 
multiple effects further downstream in the signal transducting cascade. In the A1 receptor, the 
agonist causes a conformational change leading to the activation of the G-protein. This leads to 
the binding of the GTP to the -subunit of the G-protein, which leads to the dissociation of the -
, the -subunit and the receptor. The subunits mediate the effects of GPCRs, which, in the case 
of A1 receptors, leads to inhibition of adenylyl cyclase, inhibition of Ca2+ conductance, 
stimulation of K+ conductance and activation of phospholipase C (Fredholm et al 2001). The 
subunits are active until GTPase terminates the activity by cleaving the GTP into GDP. The 
GTPase is an intrinsic part in the G-subunit, and it is controlled by proteins known as regulators 
of G-protein signalling (Neubig & Siderovski 2002). In the [35S]GTPS binding assays GTP is 
substituted by [35S]GTPS which is resistant to hydrolysis by GTPase. This means that if the 
GTPase activity itself is affected during prolonged wakefulness, the possible changes will remain 
undetected. 
As reviewed previously, there is substantial evidence indicating that adenosine mediates its sleep-
inducing effects at least partly through the A1 receptors in the cortically projecting cholinergic 
neurons in the BF. Thus it was a surprise that the G-protein activity in the BF remained 
unaffected despite the known elevated extracellular levels of adenosine during prolonged 
wakefulness (Porkka-Heiskanen et al 1997, Basheer et al 1999). There are some possible 
explanations for this lack of effect; Firstly, the A1 receptor expression is lower in the BF than in 
the cortex (Rivkees et al 1995, Dixon et al 1996), and only one third of the neurons in the BF are 
thought to be cholinergic (Gritti et al 1993). Secondly, the extracellular adenosine levels increase 
slowly within the first two hours of SD up to two-fold (Basheer et al 1999). When these factors 
are considered, it is possible that the A1 receptor dependent G-protein activity increases in the 
cholinergic cells, but that the method used is not sensitive enough to detect it. The other plausible 
explanation is that the A1 receptor dependent G-protein activity is regulated differently depending 
on the brain area, which could explain the slight increase in the G-protein activity noted in the 
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MPA, which lies in the close vicinity of the BF. When the G-protein activity is compared with 
the known time scale of the accumation of adenosine in the cortex (Basheer et al 1999), it is 
noted that the G-protein activation takes place during the first hours of deprivation, which 
corresponds to the increase phase of the adenosine levels. When the extracellular adenosine 
levels are at their highest, the G-protein activity has already returned to its normal level, i.e. to the 
same level with the undeprived control animals. It could be speculated that the A1 receptor 
dependent G-protein activity is most strongly affected by the change and not necessarily by the 
level of the extracellular adenosine. 
On the basis of these and previous studies, it is concluded that  the accumulation of adenosine 
during prolonged wakefulness causes a fast transient response in the cortex and a slower, longer 
lasting and possibly recovery sleep inducing response in the basal forebrain. 
 
4.2 The effects of sleep deprivation on the key adenosine metabolising enzymes and 
transporter activity 
 
4.2.1 The activities of the adenosine metabolising enzymes are not affected during prolonged 
wakefulness (III) 
As previously discussed, adenosine accumulates in the BF and, to a lesser extent, in the cortex 
during prolonged wakefulness. The extracellular levels of adenosine are affected by the acitivites 
of the adenosine metabolizing enzymes and the transport of adenosine between intra- and 
extracellular spaces. 
To gain insight to the possible mechanism(s) which could cause the accumulation of the 
extracellular adenosine during prolonged wakefulness, the activities of the key adenosine 
metabolizing enzymes, namely AK and 5’-NTs, were measured after 3 and 6 hours of SD and 
recovery sleep. 
There were no differences in the enzyme activities measured between the sleep deprived and the 
control animals. These findings have been confirmed, as another report was published shortly 
after our publication, in which the results were in accordance with ours, with the additional  
notion of the ADA activity remaining unaffected (Mackiewicz et al 2003). A decreasing diurnal 
tendency in the enzyme activities was noted, which is in accordance with previous findings and 
probably is due to the lower energy demand during the rest phase of the animal (Chagoya de 
Sanchez et al 1993). Despite these findings, small changes in the enzyme activities could take 
  31 
 
place during prolonged wakefulness. Firstly, the enzymes were assessed from tissue samples and 
thus the values obtained represent the mean enzyme activities of a cell population consisting of 
neurons with different transmitter phenotypes and glia. Consequently, the possible changes 
between different cell types are not noted. Secondly, all enzyme assays reflect the state of the 
selected enzymes at the moment the measurement is done, in this case after decapitation and 
dissection and freezing/melting/thawing of the tissue. Unluckily, the nucleoside metabolism is 
very rapid and tissue trauma leads to increased adenosine concentrations (Dunwiddie & Masino 
2001). Furthermore, it has been shown before that the method for killing the animals affects 
nucleoside levels (Delaney & Geiger 1996), and thus minor changes in enzyme metabolism 
might pass unnoticed. And finally, as adenosine is constantly both produced and degraded, a 
small change in the balance between consumption and production might not affect the enzyme 
activities sufficiently to be detectable by the enzyme assays. Yet it is relatively safe to assume 
that no major changes in the enzyme activities of adenosine metabolizing enzymes take place 
during prolonged wakefulness in the brain areas measured. 
 
4.2.2 The ENT1 ligand binding is decreased during prolonged wakefulness in the basal forebrain 
(IV) 
The possible sources of increased extracellular adenosine concentrations are either increased 
intracellular adenosine production due to increased activity or increased co-release of ATP, 
which is further metabolized into adenosine by the ecto-nucleotidases. Yet there is evidence that 
under basal conditions a significant amount, if not all, of adenosine originates in extracellular 
nucleotide metabolism (Delaney & Geiger 1998, Barsotti & Ipata 2004). In addition, it has been 
shown that the inhibition of the ENT1 inhibitor NBMPR into the BF and SD have similar effects 
on the extracellular adenosine levels which are approximately doubled (Porkka-Heiskanen et al 
1997, Basheer et al 1999, Porkka-Heiskanen et al 2000). 
As the enzyme activities were found to remain unaffected, the next logical step was to assess the 
other mechanism known to affect the extracellular adenosine levels, namely, the adenosine 
transport and especially the equilibrative nucleoside transporters.  
The equilibrative nucleoside transporters ENT1 and ENT2 carry nucleosides through the cell 
membrane according to the concentration gradient. Unfortunetaly there are specific tools only for 
the ENT1, for which a relatively specific inhibitor, NBMPR, is available (Thorn & Jarvis 1996). 
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To assess the possible changes in the transporter activity, the NBMPR binding and the mRNA 
expression of the ENT1 were measured after 3 and 6 hours of sleep deprivation and recovery 
sleep. The NBMPR binding was decreased in the BF of rats after 6 hours of SD but not in the 
cortex, suggesting a local decreased activity of the transporter. This would mean that regardles of 
whether the adenosine is produced intra- or extracellularly, the transport through the cell 
membrane would be less efficient. The expression of the ENT1 mRNA was not altered during SD 
when compared to controls, which could be due to the relatively short period of SD. 
The measured NBMPR binding describes the combination of the affinity of the ligand to the 
ENT1 transporter and the amount of transporters. This means that a possible change in the 
NBMPR binding can result from either a change in the affinity or in the amount of the 
transporter, and these two factors cannot be separated by this method. Despite this known deficit 
of the method, there is evidence indicating that the NBMPR binding can be used to assess the 
transporter activity (Thorn & Jarvis 1996). 
On the basis of the previous findings and the noted decrease in equilibrative transport, it is 
concluded that the accumulation of extracellular adenosine during prolonged wakefulness could 
be due to the inhibition of uptake of adenosine into the cells, and the continuous co-release of 
ATP could be due to the higher electrical activity sustained during SD. A subset of supposedly 
cholinergic neurons in the BF is known to be most active during active waking (Szymusiak et al 
2000), and when combined with the decrease of influx of adenosine into the cells it could be 
sufficient to cause the accumulation of adenosine in the BF during prolonged wakefulness. It is 
not suggested that this would be the sole mechanism to cause the accumulation of adenosine in 
the BF during prolonged wakefulness, but that the decreased activity of the ENT1 transporter is 
included in the mechanism of accumulation. There is substantial evidence showing that one 
additional mechanism could be nitric oxide (NO), as it has been shown that NO induces 
adenosine release in vitro in hippocampal slices and forebrain neuronal cultures (Fallahi et al 
1996, Rosenberg et al 2000). And quite recently it has been shown that NO donors increase 
nonREM sleep, while NO scavengers prevent recovery sleep after SD (Kalinchuk, personal 
communication). 
In the cortex, however, the extracellular adenosine levels are known to increase transiently during 
prolonged wakefulness (Porkka-Heiskanen et al 2000), while no change in the transporter activity 
was noted in this study. One possible mechanism explaining the transient increase could be 
methodological; the SD by gentle handling is based on introducing novel objects to the rats, thus 
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keeping them awake. The BF is known to be most active during situations of arousal, like in new 
surroundings, with the reported biggest difference in single unit activity being between active and 
quiet wake with a much smaller difference between quiet wake and sleep  (Szymusiak et al 
2000). Therefore the rise in the extracellular adenosine levels seen in the cortex during the first 
hours of SD could be due to the increased BF and cortical activity induced by introducing novel 
objects. It would be of interest to compare the previously noted increases in the extracellular 
adenosine levels during SD by gentle handling with another method, like the rotating disc 
method, in which no explorative behaviour is needed. 
 
4.3 The equilibrative transporters are ubiquitously distributed in the rat brain (V) 
 
The equilibrative nucleoside transporters ENT1 and ENT2 have been cloned from rat and human 
(Yao et al 1997, Griffiths et al 1997) and they have been shown to be expressed in the CNS of 
both species (Anderson et al 1999a, Anderson et al 1999b, Jennings et al 2001). The ENTs are 
membrane bound (Cabrita et al 2002) and their distribution has been assessed previously using in 
situ hybridization (ENT1 and ENT2), autoradiographic and membrane binding techniques 
(ENT1) (Geiger & Nagy 1984, Bisserbe et al 1985, Anderson et al 1999a, Anderson et al 1999b). 
These methods, while being most useful for general localization studies and activity 
measurements, give little information concerning the exact localization or amount of the 
transporter proteins per se. 
Using novel antibodies against the rat ENT1 and ENT2 raised in our laboratory, we characterized 
for the first time the distribution of the transporters using immunohistochemical methods. Both 
transporters were present in almost all neurons throughout the rat brain. The discrepancy between 
ours and previous results is clear, as Anderson et al. previously proposed that the ENT2 would be 
the pre-dominant transporter in the rat brain, due to higher prevalence of the ENT2 mRNA over 
the ENT1 mRNA positive neurons (Anderson et al 1999a, Anderson et al 1999b). Their 
proposition is based on the differences in mRNA expression; the ENT1 mRNA was present in 
approximately half of the neurons in the parietal cortex and the dorsolateral striatum, while the 
ENT2 mRNA was noted in over 90% of the neurons. The difference between our findings and 
those of Andersons is most probably methodological, as mRNA expression does not reveal the 
amount of protein, only the amount of transcript, while the immunohistochemical methods reveal 
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the localization of the protein. The protein is not a marker of transporter activity, but it is more 
accurate than the mRNA in evaluating the possible importance of the transporters. 
In the immunofluorescence and double labeling studies a major difference was noted in the 
distribution of the ENT1 and ENT2 at the cellular level; the ENT1 was located mainly in the 
cellular membrane, as expected, while the ENT2 showed in addition major somatic staining. 
Furthermore, some ENT1 and ENT2 positive astrocytes were found with the ENT1 more 
prominent of the two. In addition, a dense bundle of varicose, intensely ENT1 immunoreactive 
fibers were consistently seen in the median eminence and, to a lesser extent, in the lateral 
hypothalamus suggesting that ENT1 is located also in some axons. In accordance with previous 
studies (Anderson et al 1999a, Anderson et al 1999b), the choroid plexus and ependyme were 
strongly ENT1 and ENT2 immunoreactive, suggesting that the ENTs are involved in the forming 
of cerebrospinal fluid. 
These findings suggest that the equilibrative transporters may have different roles in the 
regulation of nucleotide transport, the ENT1 being more important in the nucleoside transport 
between the extra- and intracellular space, and the ENT2 having a more prominent role in the 
intracellular nucleoside transport between different intracellular compartments. Furthermore, the 
ENT1 seems to be located in at least some axons, but the co-localization of the ENT2 cannot be 
excluded, as the affinity of the antibody and the amount of the ENT2 may be too low to be 
detected with the methods used in the study. 
 
4.4 Future considerations 
 
The role of the ENT1 and the ENT2 in the regulation of nucleoside transport has yet many 
interesting phenomena to be investigated. The subcellular localization of both transporters is 
unknown and of major interest. Furthermore, the specific tools for studying the ENT2 are 
lacking, and thus the functional role of the transporter is still unclear. 
The focus of research shall be pointed at the intracellular localization of both the ENT 
transporters. The subcellular localization shall be assessed from cell fractions and and later 
possibly with electron microscopy as well. The CNTs have so far been studied quite sparingly, 
mostly due to the lack of specific tools, but this seems to be changing. Both the CNT1 and the 
CNT2 have been cloned from the rat brain, and their functional role reamains unclear (Anderson 
et al 1996). Moreover it has been shown that the adenosine transporter cloned from the blood 
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brain barrier is identical to the CNT2 (Li et al 2001). Most recently, evidence has been presented 
showing that the CNT2 mRNA expression is decreased in the cortex after 24 hours of SD (Duflot 
et al 2004). It seems that the concentrative nucleoside transporters are finally surfacing and it 
would be of major interest to find out the functional roles of the CNTs in the CNS and to solve 
their localization in the cellular level and their distribution between neurons of different 
transmitter phenotypes and glia.  
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5. CONCLUSIONS 
 
 The ligand binding of the A1 receptors remains unaffected during prolonged wakefulness, 
but the A1 receptor mRNA expression is increased, suggesting an increased demand for 
A1 receptors. 
 The A1 receptor-dependent G-protein activity is transiently increased during prolonged 
wakefulness in the cortex, but not in the BF.  
 The data from these studies suggest that the accumulation of adenosine causes an A1 
receptor mediated fast transient response in the cortex, and a slower, longer lasting, 
possibly recovery sleep inducing, response in the BF. 
 
 The activity of the key adenosine metabolizing enzymes remains unaffected in the cortex 
and the BF during prolonged wakefulness and recovery sleep. 
 The adenosine transporter ENT1 activity is decreased during prolonged wakefulness in 
the BF. Combined with the increased cellular activity in the BF during prolonged 
wakefulness, and thus with the increased release of ATP, this decrease of activity could 
lead to increased extracellular adenosine concentrations via the ecto-nucleotidase 
pathway. 
 
 The ENT1 and the ENT2 are widely distributed in the rat brain being present in almost all 
neurons. 
 The ENT1 is located mainly in the cellular membrane, while the ENT2 is located in the 
soma as well. This could mean that the ENT1 takes directly part in the regulation of 
extracellular levels of adenosine, and the ENT2 has a more prominent role in intracellular 
nucleoside transport. 
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